secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-05-27T20:34:57+00:00
Accession:  0001437749-26-018586
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing
--------------------------------------------------------------------------------

- Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.
- Safety and tolerability of consolidated first infusion were consistent with established BRIUMVI profile; no Grade 3 or higher infusion reactions occurred.
- Supplemental BLA submission targeted for second half of 2026 based on these results.
- If approved, BRIUMVI would be the first and only IV anti-CD20 therapy initiated with a single infusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/0001437749-26-018586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/tgtx20260527_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer